Global Life Science and High Technology company Sigma-Aldrich announced the opening of their new Asia Pacific headquarters and state-of-the-art Cell Culture Technical Center at the Biopolis Research Park in Singapore.
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global provider of life science research and clinical diagnostic products, announced financial results today for the fourth quarter and fiscal year ended
Plant Impact plc today announced that it has signed an agreement with Bayer CropScience to develop yield enhancing technologies for soy cultivation. The agreement encompasses a multi-year partnership for Plant
Pharma giants Merck, Sanofi & GSK announced their full-year results for 2014 this week, as did global AgroChemical multinational Syngenta. Syngenta reported sales of $15.1 billion USD, achieving their integrates
Thermo Fisher Scientific have announced their acquisition of ASI (Advanced Scientifics, Inc.) for a cash payment of $300 million USD as the company seeks to strengthen their bioproduction offerings. ASI
Up until now uncultured bacteria have been an untapped source of new antibiotics, but promising research published in Nature yesterday highlights novel in-situ methods for growing uncultured microorganisms. One of
Academic publishing giant Elsevier have announced the forthcoming launch of a new open access multi-disciplinary scientific journal, calling for researchers to adopt a new collaborative and open source ethos. Dr.
Controversial DNA sequencing company 23andMe announced the first of 10 deals to be signed with large biotech and pharma firms on Tuesday January 6. Their $60 million partnership with Genentech
BioReliance® Introduces Advanced In Vitro ADME and Toxicology Services Designed to Improve Drug Safety and Efficacy BioReliance® (www.bioreliance.com), Sigma-Aldrich Corporation’s (NASDAQ: SIAL) biologics and early-development services business under SAFC® Commercial
Illumina Reports Record Financial Results for Third Quarter of Fiscal Year 2014 Illumina, Inc. announced its financial results for the third quarter of 2014. Third quarter 2014 results: Revenue of
Lonza Half-Year Business Performance Fully on Track Business is fully on track with a CORE EBIT growth of 13.1% compared with the first half of 2013 despite currency headwinds Revenue
QIAGEN demonstrates expanded bioinformatics workflows at ASHG; strong market adoption as researchers analyse genomic data on more than a quarter-million samples in secure private cloud Translational research in cancer and